Lisa A. Newman, MD
In an effort to minimize the extent of surgery, targeted axillary dissection is being explored following surgery in patients with node-positive breast cancer—an exciting precision medicine approach for this population, said Lisa A. Newman, MD.
State of the Science Summit™ on Breast Cancer, Newman, director of the Breast Oncology Program at Henry Ford Cancer Institute, discussed de-escalation strategies emerging in breast cancer surgery.
OncLive: You spoke on targeted axillary surgery for patients with breast cancer. What is important to highlight here?
: We are in an era where everybody talks about precision medicine. Precision medicine is very exciting with targeted therapies. We often get into a conversation about de-escalating therapy. One of the main promises of precision medicine is trying to narrow down the treatment patients need, so that they get the targeted treatment for their specific type of breast cancer with less toxicity. Targeted therapy and de-escalating therapy is very important in medical oncology. We're also trying to de-escalate therapy when it comes to local regional management of breast cancer.
There are a lot of different strategies for performing targeted axillary dissection. We covered different strategies to avoid patients having to undergo the full axillary lymph node dissection.
Is this a widespread approach?
There are some ongoing hurdles in making targeted axillary lymph node dissection widely available across all of the healthcare facilities in the United States and beyond. It is necessary for more surgical care providers in the breast cancer arena to become familiar with the technology.
... to read the full story